Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.2.7 (
heparinase
)
1,270
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vascular endothelial growth factor
(
VEGF
) induces the proliferation of endothelial cells and is a potent angiogenic factor that binds to heparin. We have therefore studied the effect of heparin upon the interaction of
VEGF
with its receptors. Heparin, at concentrations ranging from 0.1 to 10 micrograms/ml, strongly potentiated the binding of 125I-
VEGF
to its receptors on endothelial cells. Scatchard analysis of 125I-
VEGF
binding indicates that 1 microgram/ml heparin induces an 8-fold increase in the apparent density of high affinity binding sites for
VEGF
, but does not significantly affect the dissociation constant of
VEGF
. Cross-linking experiments showed that heparin strongly potentiates the formation of the 170-, 195- and 225-kDa 125I-
VEGF
-receptor complexes on endothelial cells. At high 125I-
VEGF
concentrations (4 ng/ml), heparin preferentially enhanced the formation of the 170- and 195-kDa complexes. Preincubation of the cells with heparin, followed by extensive washes, produced a similar enhancement of subsequent 125I-
VEGF
binding. The binding of 125I-
VEGF
was completely inhibited following digestion of endothelial cells with
heparinase
and could be restored by the addition of exogenous heparin to the digested cells. The enhancing effect of heparin facilitated the detection of
VEGF
receptors on cell types that were not known previously to express such receptors. Our results suggest that cell surface-associated heparin-like molecules are required for the interaction of
VEGF
with its cell surface receptors.
...
PMID:The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. 155 17
Vascular endothelial growth factor
(
VEGF
) is a specific mitogen for endothelial cells in vitro and an angiogenic factor in vivo. Its role in other cell types is not yet clear. To explore its possible involvement in malignant transformation, we studied the expression of its receptors in normal and malignant melanocytes. Binding and cross-linking experiments showed that human melanoma cells but not normal melanocytes express
VEGF
receptors. Separation of reaction products by SDS-PAGE demonstrated the presence of 125I-
VEGF
/receptor complexes of 180 and 165 kDa in the melanoma cells. A diffuse complex with a mass of approximately 235 kDa was also detected in some experiments. Heparin enhanced the binding of the radioactive ligand to the receptors of the WW94 and SW1614 melanoma cell lines. This binding was completely abolished by
heparinase
digestion and was restored by the addition of exogenous heparin, indicating that heparin-like molecules are necessary for ligand/receptor interaction. This study suggests that the aberrant expression of
VEGF
receptors is one of the phenotypic changes occurring in melanoma cells during malignant transformation.
...
PMID:Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. 843 21
Vascular endothelial growth factor
(
VEGF
) is a family of glycoproteins with potent angiogenic activity. We reported previously that heparin has an affinity for VEGF165, the major isoform of
VEGF
, whereas 2-O-desulfated heparin and 6-O-desulfated heparin have weak but significant affinity (Ashikari-Hada, S., Habuchi, H., Kariya, Y., Itoh, N., Reddi, A. H., and Kimata, K. (2004) J. Biol. Chem. 279, 12346-12354). In this study, we first examined the effect of heparin and modified heparins (completely desulfated N-sulfated heparin, 2-O-desulfated heparin, and 6-O-desulfated heparin) on VEGF165-dependent mitogenic activity and tube formation on type I collagen gels of human umbilical vein endothelial cells. Both were enhanced by heparin, but not by modified heparins, suggesting that both the 2-O-sulfate group of hexuronic acid and the 6-O-sulfation group of N-sulfoglucosamine in heparin/heparan sulfate are necessary for VEGF165 activity. We then examined the activation of
VEGF
receptor (VEGFR) to understand the mechanism. We have made several new findings; 1) heparin yielded a 1.7-fold enhancement of VEGF165-induced phosphorylation of VEGFR-2; 2) depletion of cell surface heparan sulfate by
heparinase
/heparitinase treatment and preferential reduction of trisulfated disaccharide units of cell surface HS by sodium chlorate treatment resulted in the reduction of such phosphorylation, suggesting the involvement of a heparin-like domain in the phosphorylation of VEGFR-2; and 3) VEGF121, an isoform without the exon 7-encoded region, which has no capacity to bind to heparin, did not show these effects. It is therefore likely that a heparin-like domain of heparan sulfate/heparin forms a complex with VEGF165 and VEGFR-2 via the exon 7-encoded region, thereby enhancing VEGF165-dependent signaling.
...
PMID:Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. 1602 24